Trials / Withdrawn
WithdrawnNCT05214599
Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE)
A Phase I/II, Multicenter, Double-blind, Parallel, Randomized Trial to Assess Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults Subjects of Both Genders With Eosinophilic Esophagitis (EoE)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bazell Pharma AG · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A phase I/II, multicenter, double-blind, parallel, randomized trial to assess pharmacokinetics, efficacy, tolerability and safety of different budesonide oral gel doses in adults subjects of both genders with eosinophilic esophagitis (EoE)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Budesonide Gel | Twice daily regimen |
Timeline
- Start date
- 2021-04-23
- Primary completion
- 2024-11-01
- Completion
- 2025-04-01
- First posted
- 2022-01-28
- Last updated
- 2024-08-23
Source: ClinicalTrials.gov record NCT05214599. Inclusion in this directory is not an endorsement.